All the news Showing 10 of 448 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources TMC435-Based Therapy Significantly Improved Viral Cure Rates in Patients Who Failed Prior Treatment for Hepatitis C Business Wire / 02 November 2011 Pharmasset Takes Lead in Race to Develop Hep C Therapy By Pill The Street / 01 November 2011 Vertex study will evaluate 12-week treatment period for some hepatitis C patients Boston.com / 24 October 2011 Abbott says hepatitis C combo may be a blockbuster Reuters / 21 October 2011 Interim Phase IIb Data for Merck's VICTRELIS™ (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Market Watch (press release) / 20 October 2011 Sector Snap: Hepatitis C drug developers rise Bloomberg Business Week / 18 October 2011 Roche buys Anadys for $230 million to boost hep C business PharmaTimes / 18 October 2011 Transgene Says 3 Patients in Hepatitis Trial Had Blood Disorders Bloomberg Business Week / 12 October 2011 Pharmasset again expands hepatitis C drug study Bloomberg BusinessWeek / 11 October 2011 Vertex's Hep C Drug Needs A Growth Injection The Street / 11 October 2011 ← Prev1...3839404142...45Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds